SPP1 is associated with adverse prognosis and predicts immunotherapy efficacy in penile cancer

Hum Genomics. 2023 Dec 19;17(1):116. doi: 10.1186/s40246-023-00558-5.

Abstract

Background: The effect of SPP1 in squamous cell carcinoma of the penis (PSCC) remained unknown. We attempted to clarify the function of the SPP1 gene in PSCC.

Method: Eight paired penile cancer specimens (including penile cancer tissue, paracancerous tissue, and positive lymph node tissue) subjected to whole transcriptome sequencing were analysed to identify differentially expressed genes. We used immunohistochemistry to detect the expression of SPP1 protein and immune cell related proteins in penile cancer tissue. Then, we performed weighted gene coexpression network analysis (WGCNA) to identify the genes related to SPP1 in penile cancer tissue and positive lymph node tissue. Based on the GSE57955 dataset, the CIBERSORT and ssGSEA algorithms were carried out to investigate the immune environment of PSCC. GSVA analysis was conducted to identify the signaling pathways related to SPP1 subgroups. Enzyme-linked immunosorbent assay (ELISA) method was adopted to detect SPP1 level in the serum of 60 patients with penile cancer.

Results: Differential analysis indicated that SPP1 was the most differentially upregulated gene in both penile cancer tissues and positive lymph node tissues. Survival analysis suggested that the prognosis of the low-SPP1 group was significantly poorer than that of the high-SPP1 group. Subsequently, immune-related bioinformatics showed that SPP1 was significantly associated with B cells, CD8 + T cells, CD4 + T cells, macrophages, helper T cells, neutrophils and dendritic cells. The immunohistochemical results showed that the high-SPP1 group was characterized by relatively high expression of CD16 and relatively low expression of CD4. GSVA analysis indicated that high-SPP1 group was significantly associated with immune-related pathways such as PD-L1 expression and the PD-1 checkpoint pathway in cancer and the TNF signaling pathway. ELISA demonstrated that the serum level of SPP1 in patients with positive lymph node metastasis of penile cancer was significantly higher than that in patients with negative lymph node metastasis of penile cancer.

Conclusion: Our study shows that the SPP1 gene might be an effective biomarker for predicting the prognosis and the efficacy of immunotherapy in PSCC patients.

Keywords: Immune microenvironment; Prognosis; SPP1 gene; Squamous cell carcinoma of the penis (PSCC).

MeSH terms

  • Biomarkers, Tumor / blood
  • Carcinoma, Squamous Cell* / diagnosis
  • Carcinoma, Squamous Cell* / genetics
  • Carcinoma, Squamous Cell* / pathology
  • Carcinoma, Squamous Cell* / therapy
  • Gene Expression Profiling
  • Immunotherapy / standards
  • Osteopontin* / blood
  • Osteopontin* / genetics
  • Osteopontin* / metabolism
  • Penile Neoplasms* / diagnosis
  • Penile Neoplasms* / genetics
  • Penile Neoplasms* / pathology
  • Penile Neoplasms* / therapy
  • Sequence Analysis, RNA
  • Survival Analysis

Substances

  • SPP1 protein, human
  • Osteopontin
  • Biomarkers, Tumor